Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INOVIO PHARMACEUTICALS, INC. (INO)

Inovio Q2 net loss narrows to $6.0 million, helped by $13.9 million warrant gain

Mixed Impact 3 of 5 earnings Written later

Inovio reported a second-quarter 2026 net loss of $6.0 million, or $0.07 per share, down from $23.5 million, or $0.61 per share, a year earlier. The company said the decline was driven mainly by a $13.9 million non-cash gain on warrant liabilities, while operating expenses fell to $18.6 million from $23.1 million. Cash and short-term investments were $36.7 million at June 30, 2026, down from $58.5 million at December 31, 2025, before about $18.3 million in July offering proceeds.

Key points

  • Net loss of $6.0 million, or $0.07 per share, versus $23.5 million, or $0.61 per share, in Q2 2025
  • Non-cash warrant liability gain of $13.9 million; total operating expenses fell to $18.6 million from $23.1 million
  • Cash, cash equivalents and short-term investments of $36.7 million at June 30, 2026, excluding about $18.3 million in July offering proceeds
  • Cash expected to fund operations into late first quarter 2027, through a potential INO-3107 launch if approved; FDA PDUFA target date is October 30, 2026

The filing

CompanyINOVIO PHARMACEUTICALS, INC. (INO)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:07 PM ET
Accession number0001055726-26-000024

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.